Cargando…
Immunodominant Linear B-Cell Epitopes of SARS-CoV-2 Spike, Identified by Sera from K18-hACE2 Mice Infected with the WT or Variant Viruses
SARS-CoV-2 surface spike protein mediates the viral entry into the host cell and represents the primary immunological target of COVID-19 vaccines as well as post-exposure immunotherapy. Establishment of the highly immunogenic B-cell epitope profile of SARS-CoV-2 proteins in general, and that of the...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8875268/ https://www.ncbi.nlm.nih.gov/pubmed/35214711 http://dx.doi.org/10.3390/vaccines10020251 |
_version_ | 1784657877719318528 |
---|---|
author | Levy, Yinon Alcalay, Ron Zvi, Anat Makdasi, Efi Peretz, Eldar Noy-Porat, Tal Chitlaru, Theodor Mandelboim, Michal Mazor, Ohad Rosenfeld, Ronit |
author_facet | Levy, Yinon Alcalay, Ron Zvi, Anat Makdasi, Efi Peretz, Eldar Noy-Porat, Tal Chitlaru, Theodor Mandelboim, Michal Mazor, Ohad Rosenfeld, Ronit |
author_sort | Levy, Yinon |
collection | PubMed |
description | SARS-CoV-2 surface spike protein mediates the viral entry into the host cell and represents the primary immunological target of COVID-19 vaccines as well as post-exposure immunotherapy. Establishment of the highly immunogenic B-cell epitope profile of SARS-CoV-2 proteins in general, and that of the spike protein in particular, may contribute to the development of sensitive diagnostic tools and identification of vaccine` candidate targets. In the current study, the anti-viral antibody response in transgenic K18-hACE-2 mice was examined by implementing an immunodominant epitope mapping approach of the SARS-CoV-2 spike. Serum samples for probing an epitope array covering the entire spike protein were collected from mice following infection with the original SARS-CoV-2 strain as well as the B.1.1.7 Alpha and B.1.351 Beta genetic variants of concern. The analysis resulted in distinction of six linear epitopes common to the humoral response against all virus variants inspected at a frequency of more than 20% of the serum samples. Finally, the universality of the response was probed by cross-protective in vitro experiments using plaque-reducing neutralization tests. The data presented here has important implications for prediction of the efficacy of immune countermeasures against emerging SARS-CoV-2 variants. |
format | Online Article Text |
id | pubmed-8875268 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-88752682022-02-26 Immunodominant Linear B-Cell Epitopes of SARS-CoV-2 Spike, Identified by Sera from K18-hACE2 Mice Infected with the WT or Variant Viruses Levy, Yinon Alcalay, Ron Zvi, Anat Makdasi, Efi Peretz, Eldar Noy-Porat, Tal Chitlaru, Theodor Mandelboim, Michal Mazor, Ohad Rosenfeld, Ronit Vaccines (Basel) Article SARS-CoV-2 surface spike protein mediates the viral entry into the host cell and represents the primary immunological target of COVID-19 vaccines as well as post-exposure immunotherapy. Establishment of the highly immunogenic B-cell epitope profile of SARS-CoV-2 proteins in general, and that of the spike protein in particular, may contribute to the development of sensitive diagnostic tools and identification of vaccine` candidate targets. In the current study, the anti-viral antibody response in transgenic K18-hACE-2 mice was examined by implementing an immunodominant epitope mapping approach of the SARS-CoV-2 spike. Serum samples for probing an epitope array covering the entire spike protein were collected from mice following infection with the original SARS-CoV-2 strain as well as the B.1.1.7 Alpha and B.1.351 Beta genetic variants of concern. The analysis resulted in distinction of six linear epitopes common to the humoral response against all virus variants inspected at a frequency of more than 20% of the serum samples. Finally, the universality of the response was probed by cross-protective in vitro experiments using plaque-reducing neutralization tests. The data presented here has important implications for prediction of the efficacy of immune countermeasures against emerging SARS-CoV-2 variants. MDPI 2022-02-07 /pmc/articles/PMC8875268/ /pubmed/35214711 http://dx.doi.org/10.3390/vaccines10020251 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Levy, Yinon Alcalay, Ron Zvi, Anat Makdasi, Efi Peretz, Eldar Noy-Porat, Tal Chitlaru, Theodor Mandelboim, Michal Mazor, Ohad Rosenfeld, Ronit Immunodominant Linear B-Cell Epitopes of SARS-CoV-2 Spike, Identified by Sera from K18-hACE2 Mice Infected with the WT or Variant Viruses |
title | Immunodominant Linear B-Cell Epitopes of SARS-CoV-2 Spike, Identified by Sera from K18-hACE2 Mice Infected with the WT or Variant Viruses |
title_full | Immunodominant Linear B-Cell Epitopes of SARS-CoV-2 Spike, Identified by Sera from K18-hACE2 Mice Infected with the WT or Variant Viruses |
title_fullStr | Immunodominant Linear B-Cell Epitopes of SARS-CoV-2 Spike, Identified by Sera from K18-hACE2 Mice Infected with the WT or Variant Viruses |
title_full_unstemmed | Immunodominant Linear B-Cell Epitopes of SARS-CoV-2 Spike, Identified by Sera from K18-hACE2 Mice Infected with the WT or Variant Viruses |
title_short | Immunodominant Linear B-Cell Epitopes of SARS-CoV-2 Spike, Identified by Sera from K18-hACE2 Mice Infected with the WT or Variant Viruses |
title_sort | immunodominant linear b-cell epitopes of sars-cov-2 spike, identified by sera from k18-hace2 mice infected with the wt or variant viruses |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8875268/ https://www.ncbi.nlm.nih.gov/pubmed/35214711 http://dx.doi.org/10.3390/vaccines10020251 |
work_keys_str_mv | AT levyyinon immunodominantlinearbcellepitopesofsarscov2spikeidentifiedbyserafromk18hace2miceinfectedwiththewtorvariantviruses AT alcalayron immunodominantlinearbcellepitopesofsarscov2spikeidentifiedbyserafromk18hace2miceinfectedwiththewtorvariantviruses AT zvianat immunodominantlinearbcellepitopesofsarscov2spikeidentifiedbyserafromk18hace2miceinfectedwiththewtorvariantviruses AT makdasiefi immunodominantlinearbcellepitopesofsarscov2spikeidentifiedbyserafromk18hace2miceinfectedwiththewtorvariantviruses AT peretzeldar immunodominantlinearbcellepitopesofsarscov2spikeidentifiedbyserafromk18hace2miceinfectedwiththewtorvariantviruses AT noyporattal immunodominantlinearbcellepitopesofsarscov2spikeidentifiedbyserafromk18hace2miceinfectedwiththewtorvariantviruses AT chitlarutheodor immunodominantlinearbcellepitopesofsarscov2spikeidentifiedbyserafromk18hace2miceinfectedwiththewtorvariantviruses AT mandelboimmichal immunodominantlinearbcellepitopesofsarscov2spikeidentifiedbyserafromk18hace2miceinfectedwiththewtorvariantviruses AT mazorohad immunodominantlinearbcellepitopesofsarscov2spikeidentifiedbyserafromk18hace2miceinfectedwiththewtorvariantviruses AT rosenfeldronit immunodominantlinearbcellepitopesofsarscov2spikeidentifiedbyserafromk18hace2miceinfectedwiththewtorvariantviruses |